Merck

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Merck 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About MRK

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. 

CEO
Robert M. Davis
CEORobert M. Davis
Employees
75,000
Employees75,000
Headquarters
Rahway, New Jersey
HeadquartersRahway, New Jersey
Founded
1891
Founded1891
Employees
75,000
Employees75,000

MRK Key Statistics

Market cap
314.89B
Market cap314.89B
Price-Earnings ratio
35.92
Price-Earnings ratio35.92
Dividend yield
2.63%
Dividend yield2.63%
Average volume
9.37M
Average volume9.37M
High today
$131.74
High today$131.74
Low today
$127.03
Low today$127.03
Open price
$128.45
Open price$128.45
Volume
13.47M
Volume13.47M
52 Week high
$131.74
52 Week high$131.74
52 Week low
$76.66
52 Week low$76.66

Stock Snapshot

As of today, Merck(MRK) shares are valued at $127.51. The company's market cap stands at 314.89B, with a P/E ratio of 35.92 and a dividend yield of 2.63%.

On 2026-07-18, Merck(MRK) stock traded between a low of $127.03 and a high of $131.74. Shares are currently priced at $127.51, which is +0.4% above the low and -3.2% below the high.

Merck(MRK) shares are trading with a volume of 13.47M, against a daily average of 9.37M.

During the past year, Merck(MRK) stock moved between $76.66 at its lowest and $131.74 at its peak.

During the past year, Merck(MRK) stock moved between $76.66 at its lowest and $131.74 at its peak.

MRK News

Investor's Business Daily 22h
Merck Reportedly Goes To Bat In Takeover Battle. Genomics Stock Flies.

Technology Merck Reportedly Goes To Bat In Takeover Battle. Genomics Stock Flies. Licensing Personalis (PSNL) stock popped Friday on a rumor Merck (MRK) and at...

Merck Reportedly Goes To Bat In Takeover Battle. Genomics Stock Flies.
Seeking Alpha 23h
Personalis is said to have attracted takeover interest from Merck

Personalis (PSNL) shares added ~4% in the premarket on Friday following a report indicating that the company is exploring a potential sale after receiving takeo...

Personalis is said to have attracted takeover interest from Merck
TipRanks 1d
Personalis price target raised to $17 from $12 at Needham

Needham raised the firm’s price target on Personalis (PSNL) to $17 from $12 and keeps a Buy rating on the shares following a blog report that the company has re...

Analyst ratings

66%

of 29 ratings
Buy
65.5%
Hold
27.6%
Sell
6.9%

More MRK News

TipRanks 1d
Merck Rated Buy as Lipfendra Launch and Cardiovascular Pipeline Support Outlook; Price Target Maintained at $141

Merck & Company, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Jason Gerberry from Bank of America Securities maintai...

Simply Wall St 1d
Did FDA’s First Oral PCSK9 Approval Just Recast Merck’s Pipeline-Driven Growth Narrative?

Earlier this week, Merck & Co. received U.S. FDA approval for LIPFENDRA (enlicitide), the first once-daily oral PCSK9 inhibitor, after Phase 3 trials showed sub...

Did FDA’s First Oral PCSK9 Approval Just Recast Merck’s Pipeline-Driven Growth Narrative?
Barron's 2d
Merck Stock Rises After U.S. Approval for Powerful Cholesterol-Cutting Pill

Biotech and Pharma Merck Stock Rises After U.S. Approval for Powerful Cholesterol-Cutting Pill In this article AMGN REGN SAN AZN Merck stock is up around 17% so...

Merck Stock Rises After U.S. Approval for Powerful Cholesterol-Cutting Pill
TipRanks 2d
Merck’s Lipfendra approved by FDA for adults with hypercholesterolemia

Merck (MRK) announced the FDA has approved hypercholesterolemia – enlicitide – tablets 20 mg as an adjunct to diet and exercise to reduce low-density lipoprotei...

TipRanks 2d
Merck Buy Rating Reiterated as sac-TMT Data De-Risk Oncology Pipeline; 12-Month Price Target Maintained at $137

Goldman Sachs analyst Asad Haider maintained a Buy rating on Merck & Company yesterday and set a price target of $137.00. TipRanks has entered a new arena in t...

Simply Wall St 2d
Is Merck Undervalued As KEYTRUDA Wins New FDA Approvals And Phase 3 Success?

Merck (MRK) is back in focus after two fresh KEYTRUDA milestones, new FDA approvals for bladder cancer regimens with Padcev, and Phase 3 success in endometrial...

Is Merck Undervalued As KEYTRUDA Wins New FDA Approvals And Phase 3 Success?
24/7 Wall St. 3d
Prediction: This Dividend King Could End The Year With a New All-Time High Stock Price

Prediction: This Dividend King Could End The Year With a New All-Time High Stock Price By Vandita Jadeja Published Jul 15, 1:29PM EDT Quick Read JNJ earns a B...

Prediction: This Dividend King Could End The Year With a New All-Time High Stock Price

People also own

Based on the portfolios of people who own MRK. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.